Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys RARE Stock

Rep. Gilbert Ray Cisneros Jr. bought shares of Ultragenyx Pharmaceutical Inc. (RARE) on September 29, 2026, valued between $1,001 and $15,000. This purchase was disclosed in a periodic transaction report filed under the STOCK Act on October 12, 2026. Cisneros, a Democrat representing California's 31st district, is showing interest in the biotechnology sector, which focuses on rare diseases.

What Changed in Gilbert Ray Cisneros Jr.'s Position

Cisneros Jr. made this purchase as part of his investment strategy, which reflects an ongoing interest in companies working on innovative treatments.

Other Institutional Activity in Ultragenyx Pharmaceutical

Several institutional investors have shown interest in Ultragenyx. Blackrock Inc. grew its holdings by 3,354,827 shares, ending with 10,654,276 shares worth about $154.9 million. RTW Investments LP added 4,148,030 shares, bringing its total to 7,796,895 shares valued at approximately $113.4 million. Vanguard Portfolio Management LLC increased its position by 1,404,131 shares, totaling 6,790,135 shares worth around $98.7 million. AQR Capital Management, LLC also expanded its stake by 1,982,755 shares, reaching 6,560,809 shares valued at about $95.4 million. Finally, State Street Corporation increased its holdings by 1,137,351 shares, totaling 6,158,766 shares worth around $89.5 million.

Ultragenyx Pharmaceutical Inc. Stock Up 2.5%

Ultragenyx shares recently traded around $14.87 as of October 16, 2026. The stock's performance is particularly interesting given its focus on rare genetic diseases, which often attract specialized investment due to their unique market potential. Investors may find it noteworthy that the stock has faced volatility, especially in the context of its recent trading history.

Recent Earnings

Ultragenyx reported a revenue of $717 million for the trailing twelve months, showcasing a year-over-year growth of 28.1%. However, the company is currently operating at a net margin of -81.7%, indicating ongoing challenges in profitability. The next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at Ultragenyx Pharmaceutical Inc.

Before Cisneros's purchase, several insiders sold shares. Karah Herdman Parschauer, an officer, sold 1,900 shares on August 3, 2026, at an average price of $24.92, totaling approximately $47,348. Chief Financial Officer Howard Horn sold 4,696 shares on the same day for about $117,024. Additionally, Theodore Alan Huizenga sold 1,283 shares on September 15, 2026, at an average price of $13.57, valued at roughly $17,410.

Analysts Set New Price Targets

On September 18, 2026, Morgan Stanley maintained an Equal-Weight rating with a price target of $20, up from $18. Citigroup also maintained a Buy rating with a target of $32, increased from $31. Canaccord Genuity kept its Buy rating with a target of $39, rising from $37. Evercore ISI Group maintained an In-Line rating with a target of $18, up from $16, while Barclays kept its Overweight rating with a target of $35, increased from $32. The consensus among analysts suggests a strong interest in the company, with a mean price target reflecting positive sentiment.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company headquartered in Novato, California. It focuses on developing treatments for rare and ultra-rare genetic diseases. With a workforce of about 1,371 employees, the company aims to bring innovative therapies to patients worldwide, which is critical for investors interested in the biotechnology sector.

Bottom Line

Cisneros's latest purchase indicates an ongoing interest in the healthcare sector, particularly in companies like Ultragenyx that focus on rare diseases. Investors should watch for the upcoming earnings report on November 3, 2026, for further insights into the company’s performance. This trade adds to the context of his previous transactions, including a sale of shares in Workday on June 5, 2026.